Description
To assess the efficacy of a nitric oxide nasal spray (NONS) in the reduction of risk of symptomatic coronavirus disease-19 (COVID-19) infection, reduction of the need for medical intervention resulting from COVID19; and assess tolerability …
Amendment chain · 3 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $500,000 at start, $5,500,000 after amendment #4 (+$5,000,000).
- #02022-02-14$500,000
- #32023-02-20$6,500,000+$6,000,000
- #42023-11-20$5,500,000-$1,000,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2022-02-14(start date) | $500,000 | — | To assess the efficacy of a nitric oxide nasal spray (NONS) in the reduction of risk of symptomatic coronaviru… |
| #3 amendment | 2023-02-20 | $6,500,000 | +$6,000,000 | To assess the efficacy of a nitric oxide nasal spray (NONS) in the reduction of risk of symptomatic coronaviru… |
| #4 amendment | 2023-11-20 | $5,500,000 | −$1,000,000 | To assess the efficacy of a nitric oxide nasal spray (NONS) in the reduction of risk of symptomatic coronaviru… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 710549726)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2024-2025-Q4-1025921 | National Research Council Canada | Conseil national de recherches Canada · CanExport SME | $28,500 | FY2025 |
| 172-2023-2024-Q4-1014548 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $67,416 | FY2024 |
| 172-2023-2024-Q2-1009785 | National Research Council Canada | Conseil national de recherches Canada · CanExport SME | $24,000 | FY2024 |
| 172-2021-2022-Q4-985935 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $5,375 | FY2022 |
| 172-2021-2022-Q3-981971 | National Research Council Canada | Conseil national de recherches Canada · CanExport SMEs | $35,000 | FY2022 |
| 172-2020-2021-Q1-948557 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $400,000 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2021-2022-Q4-987525 · retrieved 2026-11-12.